PRF in Management of Chronic Multiple Oral Ulcers
CompletedPhase 1NCT03878771
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
PRF in orabase will be applied as a pack material on chronic oral ulcers of chronic multiple oral lesions compared to conventional topical steroid therapy with clobetasol propionate 0.05% in orabase. The outcomes measured are Pain alleviation as Primary outcome and Clinical improvement in terms of Ulcer size, Number and Mucositis score as Secondary outcomes. Time frame for outcomes assessment will be Daily for 7 Days regarding pain score and weekly for 2 weeks regarding clinical improvement.
Study details
- Official title
- Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers
- Conditions
- Oral Ulcer Due to Pemphius Vularis
- Oral Ulcer Due to Benign Mucous Membrane Pemphioid
- Oral Ulcer Due to Steven Johnson's Syndrome
- Interventions
- Biological: Platelet rich fibrin gel in Orabase
- Drug: Dermovate cream in Orabase
- Sponsor
- Beni-Suef University
- Start date
- 2019-03-13
- Primary completion
- 2019-04-15
- Sex
- All
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with Oral ulcers due to Benin mucous membrane pemphioid, Pemphius vulgaris and Steven Johnson's Syndrome with mucositis score 4 and pain score 10 Exclusion Criteria: * patients with any systemic other systemic condition
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03878771